ArticleThe Journal of endocrinology2017
Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia.
Article in The Journal of endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Genomic regions, candidate genes, and pleiotropic variants associated with physiological and anatomical indicators of heat stress response in lactating sows.BMC genomics · 2024Article
- Neurotensin expression, regulation, and function during the ovulatory period in the mouse ovary†.Biology of reproduction · 2023Article
- Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer.Cancers · 2020Article
- ELL2 Is Required for the Growth and Survival of AR-Negative Prostate Cancer Cells.Cancer management and research · 2020Article
- Conditional Deletion of Eaf1 Induces Murine Prostatic Intraepithelial Neoplasia in Mice.Neoplasia (New York, N.Y.) · 2019Article
- Association of High miR-182 Levels with Low-Risk Prostate Cancer.The American journal of pathology · 2019Article
- Anti-apoptotic factor Birc3 is up-regulated by ELL2 knockdown and stimulates proliferation in LNCaP cells.American journal of clinical and experimental urology · 2019Article
- Regulation of ELL2 stability and polyubiquitination by EAF2 in prostate cancer cells.The Prostate · 2018Article
- ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells.Cancer letters · 2018Article
- Concurrent EAF2 and ELL2 loss phenocopies individual EAF2 or ELL2 loss in prostate cancer cells and murine prostate.American journal of clinical and experimental urology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 4 countries.
Funding
Abstract
Elongation factor, RNA polymerase II, 2 (ELL2) is an RNA Pol II elongation factor with functional properties similar to ELL that can interact with the prostate tumor suppressor EAF2. In the prostate,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.